CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020 Revenues increased to CHF 1.3 million driven by strong MagnetOs sales, up 42% versus H1 2019 Net operating costs of CHF 7.5 million led by higher marketing expenses Several trial sites activated for the Fibrin-PTH phase II clinical study, […]
continue readingKuros Biosciences further strengthens orthobiologics patent portfolio
. Grant of European patent entitled ‘Osteoinductive composites’ Notice of allowance of Japanese patent from the same patent family Further strengthens Kuros’s position as a leader in the field of orthobiologics Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has been granted the European patent, EP 3268058, entitled ‘Osteoinductive composites’. […]
continue reading